News & Events about Merus Nv.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive ...
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (NRG1+) cancer have been treated with zenocutuzumab (Zeno) monotherapy - Petosemtamab clinical update planned for first half of 2023 - MCLA-129 clinical update planned for second half of 2023 - Based on the Companys current...
Summit Therapeutics (NASDAQ:SMMT Get Rating) and Merus (NASDAQ:MRUS Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, ...
Globe Newswire
3 months ago
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced that Bill Lundberg, M.D., President, Chief Executive ...
Market News Video
3 months ago
Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned dollars to make a purchase, is that they expect to make money. Today we look at two ...